Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rotterdam Edoxaban Leaflet Evaluation in Patients after Transcatheter Aortic Valve Implantation Rotterdam Edoxaban Klepblad evaluatie bij patienten na een percutane aortaklep vervanging

Next Previous
Trial Profile

Rotterdam Edoxaban Leaflet Evaluation in Patients after Transcatheter Aortic Valve Implantation Rotterdam Edoxaban Klepblad evaluatie bij patienten na een percutane aortaklep vervanging

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Edoxaban (Primary)
  • Indications Aortic valve stenosis; Thrombosis
  • Focus Therapeutic Use
  • Acronyms REDOX-TAVI

Most Recent Events

  • 01 Feb 2025 Status changed to completed.
  • 01 Feb 2025 Results published in the Catheterization and Cardiovascular Interventions
  • 06 Apr 2024 This trial has been completed in Netherlands according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top